The Antihypertensive Drug Telmisartan Protects Oligodendrocytes from Cholesterol Accumulation and Promotes Differentiation by a PPAR-γ-Mediated Mechanism

• Published in: International journal of molecular sciences 2021-09, Vol.22 (17), p.9434
• Main Authors: Bernardo, Antonietta, Malara, Mariagiovanna, Bertuccini, Lucia, De Nuccio, Chiara, Visentin, Sergio, Minghetti, Luisa
• Format: Article
• Language: English
• Subjects: Accumulation; Agonists; Angiotensin AT1 receptors; Angiotensin II; Antihypertensives; Cholesterol; cholesterol accumulation; Cognitive ability; Differentiation; Drug dosages; drug repositioning; Gene expression; Inflammation; Ligands; Lysosomes; Metabolism; Morphology; Myelin; myelination; Niemann Pick type C disease; Niemann-Pick disease; Npc1 protein; oligodendrocyte progenitors; Oligodendrocytes; Peroxisome proliferator-activated receptors; Phenotypes; PPAR-γ; Proteins
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22179434

Our previous studies have demonstrated that specific peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists play a fundamental role in oligodendrocyte progenitor (OP) differentiation, protecting them against oxidative and inflammatory damage. The antihypertensive drug Telmisartan (TLM) was shown to act as a PPAR-γ modulator. This study investigates the TLM effect on OP differentiation and validates its capability to restore damage in a pharmacological model of Niemann-Pick type C (NPC) disease through a PPAR-γ-mediated mechanism. For the first time in purified OPs, we demonstrate that TLM-induced PPAR-γ activation downregulates the type 1 angiotensin II receptor (AT1), the level of which naturally decreases during differentiation. Like other PPAR-γ agonists, we show that TLM promotes peroxisomal proliferation and promotes OP differentiation. Furthermore, TLM can offset the OP maturation arrest induced by a lysosomal cholesterol transport inhibitor (U18666A), which reproduces an NPC1-like phenotype. In the NPC1 model, TLM also reduces cholesterol accumulation within peroxisomal and lysosomal compartments and the contacts between lysosomes and peroxisomes, revealing that TLM can regulate intracellular cholesterol transport, crucial for myelin formation. Altogether, these data indicate a new potential use of TLM in hypomyelination pathologies such as NPC1, underlining the possible repositioning of the drug already used in other pathologies.